Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
about
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraftOver-expression of semaphorin4D, hypoxia-inducible factor-1α and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer.Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinomaUnderstanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions.Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients.Adrenomedullin promotes angiogenesis in epithelial ovarian cancer through upregulating hypoxia-inducible factor-1α and vascular endothelial growth factor.Suppression of lymph node and lung metastases of endometrial cancer by muscle-mediated expression of soluble vascular endothelial growth factor receptor-3.Adenoviral vector encoding soluble Flt-1 engineered human endometrial mesenchymal stem cells effectively regress endometriotic lesions in NOD/SCID mice.
P2860
Q35592388-DF210F8C-44AC-4AE0-A991-359B8059EB6AQ36396554-8FEC69B1-E18B-46AD-A47A-6AF37F334167Q36414302-03551277-0B13-4BB7-BB1A-520B88D4612BQ36808641-26F98DE4-CF05-46F0-B509-F1B987A0658CQ36865053-44FB551C-61D7-4DF0-A700-7724C9F20879Q37587599-313E8990-F230-4017-A877-6ABA23065FB8Q39161305-BED81048-2154-4B6A-B7D1-D2C029EAC8AAQ40846016-94B16D10-91DE-45B7-8C3A-2BE9F3E7ECCB
P2860
Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Antiangiogenic gene therapy wi ...... with human ovarian carcinoma.
@en
Antiangiogenic gene therapy wi ...... with human ovarian carcinoma.
@nl
type
label
Antiangiogenic gene therapy wi ...... with human ovarian carcinoma.
@en
Antiangiogenic gene therapy wi ...... with human ovarian carcinoma.
@nl
prefLabel
Antiangiogenic gene therapy wi ...... with human ovarian carcinoma.
@en
Antiangiogenic gene therapy wi ...... with human ovarian carcinoma.
@nl
P2093
P2860
P50
P356
P1476
Antiangiogenic gene therapy wi ...... with human ovarian carcinoma.
@en
P2093
Anniina Laurema
Hanna Sallinen
Jonna K Koponen
Kirsi Hamalainen
Laura Tuppurainen
Maarit Anttila
Minna Sopo
Pasi Tuunanen
Svetlana Laidinen
P2860
P304
P356
10.1002/IJC.27495
P577
2012-03-27T00:00:00Z